Innovative public-private collaboration launches to tackle antibiotic research
WorldPharmaNews, May 25, 2015-
GlaxoSmithKline and AstraZeneca welcomed the launch of a pioneering approach to antibiotic research in Europe that will see pharmaceutical and biotechnology companies working alongside public partners to tackle the rising threat from antibiotic resistance and address some of the key barriers to the development of effective antibiotics.
The objective of the proposed research programme is to improve the underlying scientific understanding of antibiotic resistance, design and implement efficient clinical trials and take novel drug candidates through clinical development. Supported by the Innovative Medicines Initiative (IMI), Europe’s largest public-private initiative, the research programme’s first projects will be funded by a joint budget of up to € 223.7 million – € 109 million provided by IMI and € 114.7 million in kind contributions from the pharmaceutical and biotechnology companies involved.
Antibiotic resistance is increasingly becoming a worldwide health threat. Many of the medical advances in recent years, such as chemotherapy for cancer treatment and organ transplantation, depend on effective antibiotics. Despite this need and the continued emergence of bacteria resistant to existing drugs, research has diminished over the past 15 years and few companies remain active in this area.
Short URL: http://www.worldhealthconnection.com/?p=6022